
Shares of biopharmaceutical company Gilead Sciences GILD.O fall 2.9% to $115.34 in premarket
Reuters reports CVS Health CVS.N to not add Gilead's new HIV prevention drug Yeztugo to its commercial plans for now
CVS cites clinical, financial, and regulatory reasons for decision, a spokesperson told Reuters
Adds, won't cover Yeztugo under its Affordable Care Act formularies, which follow U.S. Department of Health and Human Services (HHS) recommendations
Gilead still negotiating with CVS over Yeztugo; U.S. list price more than $28,000/year
Co aims for 75% U.S. insurer coverage by year-end and 90% by June 2026
A majority of brokerages rate the stock "buy" or higher; their median PT is $128
Up to last close, stock had risen over 28.5% YTD